Brainsway Ltd
TASE:BWAY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
937.1
2 026
|
Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Brainsway Ltd
Total Liabilities & Equity
Brainsway Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
Brainsway Ltd
TASE:BWAY
|
Total Liabilities & Equity
$63m
|
CAGR 3-Years
23%
|
CAGR 5-Years
22%
|
CAGR 10-Years
13%
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Total Liabilities & Equity
$218.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
158%
|
CAGR 10-Years
N/A
|
||
Inmode Ltd
NASDAQ:INMD
|
Total Liabilities & Equity
$824m
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
||
Sisram Medical Ltd
HKEX:1696
|
Total Liabilities & Equity
$626.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
||
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Total Liabilities & Equity
$43.5m
|
CAGR 3-Years
108%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
E
|
Epitomee Medical Ltd
TASE:EPIT
|
Total Liabilities & Equity
$40.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Brainsway Ltd
Glance View
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
See Also
What is Brainsway Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
63m
USD
Based on the financial report for Dec 31, 2023, Brainsway Ltd's Total Liabilities & Equity amounts to 63m USD.
What is Brainsway Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
13%
Over the last year, the Total Liabilities & Equity growth was -2%. The average annual Total Liabilities & Equity growth rates for Brainsway Ltd have been 23% over the past three years , 22% over the past five years , and 13% over the past ten years .